Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entrectinib in ROS1-positive Rare Cancers (DETERMINE Arm 03)
NCT05770544Phase 3Recruiting
- Sponsor
- Cancer Research UK
- Start
- Nov 2025
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of entrectinib in solid tumor, hematologic malignancy, central nervous system tumor, sponsored by Cancer Research UK. Started Nov 2025; status: recruiting.
02
Drugs
entrectinib
03
Conditions
solid tumorhematologic malignancycentral nervous system tumor
Beyond the preview
Go deeper on NCT05770544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05770544.